Company Profile
Galectin Therapeutics Stock Price, News & Analysis
- Ticker:
- GALT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.22 USD (+4.21%)
Close
Last updated: August 6, 2026
159M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, GALT closed up 4.21% at $3.22. No new same-company headline was identified in the current news window.
Company overview
Business overview
Galectin Therapeutics is a biotechnology company focused on fibrosis and metabolic-liver disease biology. Its story is centered on immune and fibrotic pathways in serious disease.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Galectin sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical data, target validation, and the chance to build value in liver and fibrosis disease.
Position Within the Biotechnology Landscape
Galectin is a catalyst-driven liver-disease name whose stock reacts strongly to development updates.
Future catalysts
Galectin’s catalysts are belapectin and fibrosis / oncology updates, with any clinical step determining whether the program still has room. The company needs a stronger human signal to keep the story alive.
Recent news
- 01
- 02
- 03
- 04
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
Source: Galectin Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Galectin Therapeutics (GALT)?
Galectin Therapeutics (GALT) most recently closed at 3.22 USD, a +4.21% move versus the previous session.
What is the market cap of Galectin Therapeutics (GALT)?
Galectin Therapeutics currently has a market capitalization of 159M USD on BioPharmSignal.
What does Galectin Therapeutics do?
Galectin Therapeutics is a biotechnology company focused on fibrosis and metabolic-liver disease biology. Its story is centered on immune and fibrotic pathways in serious disease.
On which exchange is GALT stock listed?
Galectin Therapeutics (GALT) is associated with NASDAQ, United States, Biopharma.
What is Galectin?
Galectin’s catalysts are belapectin and fibrosis / oncology updates, with any clinical step determining whether the program still has room.
Which conditions is Galectin Therapeutics targeting with Galectin?
Galectin Therapeutics is associated with oncology, metabolic disease based on its company overview and current catalyst commentary.
How does Galectin Therapeutics describe recent progress with Galectin?
Galectin’s catalysts are belapectin and fibrosis / oncology updates, with any clinical step determining whether the program still has room.
What is Therapeutics?
Galectin Therapeutics is a biotechnology company focused on fibrosis and metabolic-liver disease biology.